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0939-4753/ª 2015 Elsevier B.V. All rights reseAbstract Background and aims: The positive and negative health effects of dietary carbohy-
drates are of interest to both researchers and consumers.
Methods: International experts on carbohydrate research held a scientiﬁc summit in Stresa, Italy,
in June 2013 to discuss controversies surrounding the utility of the glycemic index (GI), glycemic
load (GL) and glycemic response (GR).
Results: The outcome was a scientiﬁc consensus statement which recognized the importance of
postprandial glycemia in overall health, and the GI as a valid and reproducible method ofex, Glycemic Load and Glycemic Response: an International Scientiﬁc Consensus Summit” held in Stresa
ion and Risk Factor Modiﬁcation Centre, St. Michael’s Hospital, 61, Queen St. East, 6th Floor, Toronto, Ontario,
; fax: þ1 416 867 7495.
to.ca (L.S.A. Augustin).
rved.
796 L.S.A. Augustin et al.classifying carbohydrate foods for this purpose. There was consensus that diets low in GI and GL
were relevant to the prevention and management of diabetes and coronary heart disease, and
probably obesity. Moderate to weak associations were observed for selected cancers. The group
afﬁrmed that diets low in GI and GL should always be considered in the context of diets other-
wise understood as healthy, complementing additional ways of characterizing carbohydrate
foods, such as ﬁber and whole grain content. Diets of low GI and GL were considered particularly
important in individuals with insulin resistance.
Conclusions: Given the high prevalence of diabetes and pre-diabetes worldwide and the consis-
tency of the scientiﬁc evidence reviewed, the expert panel conﬁrmed an urgent need to commu-
nicate information on GI and GL to the general public and health professionals, through channels
such as national dietary guidelines, food composition tables and food labels.
ª 2015 Elsevier B.V. All rights reserved.Introduction
Dietary carbohydrates have received negative publicity in
the last decade following the popularity of high protein
diets for weight loss, and the more recent ﬁnds that car-
bohydrates may be ‘worse than saturated fats’ for cardio-
vascular disease (CVD) risk [1,2]. These landscape changes
have raised questions about the amount and type of car-
bohydrate to be recommended in healthy diets. Now the
majority of carbohydrate-containing foods consumed in
industrialized nations are of poor quality (e.g. higher in GI
and GL as well as low in dietary ﬁber and calorie-dense).
Generally foods are now of the kind that are quickly
digested, absorbed and give rise to high blood glucose and
insulin ‘spikes’. As overweight, obesity and insulin resis-
tance have become more prevalent, concerns for the
amount and type of carbohydrate consumed has increased
because of the changed view that carbohydrate nutrition
can increase rather than (as originally perceived) only
decrease cardiometabolic risk. Thus evidence has sup-
ported that some carbohydrate sources can be beneﬁcial,
while others are not, depending on both their glycemic
index and ﬁber content [2e6]. Accordingly a meeting was
organized in Stresa (Italy) titled “Glycemic Index (GI),
Glycemic Load (GL) and Glycemic Response (GR): an In-
ternational Scientiﬁc Consensus Summit”. The purpose of
the summit was to bring together international experts in
the ﬁeld of carbohydrates, glycemic index, ﬁber and health
in order to present and discuss the issues related to the
role of the dietary GI, GL and GR in the prevention and
management of chronic diseases. Discussion points
addressed areas of agreement, areas of further investiga-
tion, and areas that should be communicated to the public.
Over two days and eight sessions, the expert group dis-
cussed the relevance of dietary carbohydrates and post-
prandial glycemia to health, covering historical perspectives,
analytical issues, chronic disease, metabolism, body weight,
novel health effects, health claims and future research. Two
sessions were devoted to food industry concerns. The pro-
gram speciﬁcally addressed the following issues:
 Postprandial glycemia: should it be lowered?
 If yes, how should it be achieved? What does the GI measure?
 GI methodology
 Strengths and weakness of the terms GI, GL and GR
 Testing foods, meals or the overall diet
 Simple sugars, fructose and low GI diets
 Different ways of lowering GI and GL
 GI and GL in diabetes prevention and management
 GI and GL in CHD risk
 GI and GL in cancer risk
 GI and GL and satiety
 GI and GL in overweight and obesity
 GI and GL and chronic inﬂammation
 GI and GL in childhood and adolescence
 GI and GL in different dietary patterns
 LowGIdiets in thecontextof ahealthyMediterraneandiet
 The appropriateness of GI in national/international
nutrition guidelines
 Consensus: what can we agree upon?
 Looking to the future and planning new research
The outcome of this ﬁrst international summit was a
consensus statement comprising 20 points of agreement
that could be utilized by scientists, industry, health
agencies and governmental bodies. In addition, the Inter-
national Carbohydrate Quality Consortium (ICQC) was
ofﬁcially formed with intention to meet on a bi-annual
basis both to bring clarity to the controversy surrounding
the health effects of carbohydrates and to increase
awareness of healthy carbohydrate choices.Deﬁnitions
Basic deﬁnitions are given to clarify terminology used at
present: GR is the post-prandial blood glucose response
(change in concentration) elicited when a food or meal
that contains carbohydrate is ingested. Available carbohy-
drate is the carbohydrate in foods that is digested, absor-
bed and metabolized as carbohydrate and it is sometimes
referred to as net carbohydrate or glycemic carbohydrate
(expressed as the monosaccharide equivalent for optimal
comparability between carbohydrates) [7]. The GI is
conceptually the GR elicited by a portion of food
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bohydrate and is expressed as a percentage of the GR eli-
cited by 50 g (or 25 g) of the reference carbohydrate (i.e.
either a glucose solution or white wheat bread, deﬁned
respectively as the glucose scale or the bread scale). GI is
precisely deﬁned by the ISO (International Organization
for Standardization) method 26642:2010 (http://www.iso.
org/iso/home/store/catalogue_tc/catalogue_detail.htm?
csnumberZ43633). The GI is therefore both a standard-
ized GR (based on an equal amount of available carbohy-
drate) and a relative GR (relative to a referent food). It is a
property of the food itself, an index or percentage repre-
senting a quality of carbohydrate foods. Foods having
carbohydrate that is digested, absorbed and metabolized
quickly are considered high GI foods (GI  70 on the
glucose scale) whereas those that are digested, absorbed
and metabolized slowly are considered low GI foods
(GI  55 on the glucose scale). The GL is the product of GI
and the total available carbohydrate content in a given
amount of food (GL Z GI  available carbohydrate/given
amount of food). Available carbohydrates can have
different modes of expression, for example: gram (g) per
serving, g per 100 g food, g per day’s intake, and g per
1000 kJ or 1000 kcal (1 kcal Z 4.184 kJ). Thus depending
on the context in which GL is used, the GL has corre-
sponding units of g per serving, g per 100 g food, and g per
1000 kJ or 1000 kcal.
Presentations summaries
Glycemic index: history and clinical implications5
One of the major dietary changes from the ancient to the
modern world has been the increased consumption of
ﬁber-depleted processed carbohydrate foods, coincident
with rising rates of obesity and diabetes [8,9] and with
great concern for increasing CHD risk. Pharmacological
approaches to improve glycemic control in type 2 diabetes
(T2DM) in large clinical trials have been shown useful but
additional improvements in diabetes control have been
demonstrated when diets of lower rather than higher GI
are eaten [10e13]. Moreover, tight pharmacologic glycemic
control has to date failed to show the anticipated clear
beneﬁts for CHD among T2DM patients, hence pharma-
cotherapy may represent only a partial solution [14]. These
ﬁndings suggest that certain dietary approaches that both
improve blood glucose control and reduce CHD risk and
risk factors should also be emphasized. One of these ap-
proaches may include reducing the rate of digestion, ab-
sorption and metabolism of carbohydrate by the low GI of
foods. The relevance of the GI continues to be debated.
Since the ﬁrst GI publication in 1981 [15], there has been a
growing body of evidence suggesting the potential
importance of GI/GL in diabetes, CVD, cancer and body
weight management. International GI tables were devel-
oped in 1995 and later updated in 2002 and 2008 [16] with
the GL concept ﬁrst introduced by Walter Willett and5 Author of the section: Jenkins D.J.A.colleagues in 1997 [17]. Large epidemiological in-
vestigations have shown that the combination of low GL
and high cereal ﬁber intake reduced T2DM risk by 2-fold in
men and women [17,18]. More recently these trends have
been conﬁrmed in both men and women, with greater risk
reduction in women [19]. CHD risk was also reduced with
low GL [6] and with low GI diets [20] again shown clearly
in women, as well as risk of certain cancers, mainly breast
and colorectal although not all studies have demonstrated
these beneﬁts [11,21e23]. There are also studies linking
modiﬁcation of risk factors for these diseases to differ-
ences in dietary GI. Meta-analyses demonstrated that low
GI diets signiﬁcantly improved glycemic control [13] and
LDL-cholesterol [24], and in single studies, risk factors such
as plasminogen activator inhibitor-1 [25,26], and c-reac-
tive protein, particularly at higher BMI (>25 kg/m2), both
in epidemiological investigations [27] and in clinical trials
[28,29]. The mechanism responsible for these beneﬁcial
effects may relate to the slow absorption of carbohydrate
typically seen with the use of low GI foods, viscous ﬁbers
and Acarbose, the alpha-glucoside hydrolase inhibitor.
Acarbose through its inhibition of pancreatic amylase and
brush border sucrase-isomaltase inhibits both starch
digestion and the uptake of sugar and di- and tri-
saccharide products of starch digestion thus reducing
postprandial glycemia. It therefore transforms the diet into
a low GI diet [30]. Acarbose in combination with a habitual
diet in the STOP NIDDM trial has been shown to reduce
new cases of diabetes (36%), CVD (49%) and hyperten-
sion (34%) [31,32]. A meta-analysis of 7 clinical trials
using acarbose conﬁrmed the reduction in cardiovascular
events and risk factors, including triglycerides, blood
pressure and body weight [33]. Other alpha-glucoside
hydrolase inhibitors have been tested and have
conﬁrmed the postprandial blood glucose lowering effect
and diabetes risk reduction [34,35]. Notably, these studies
with inhibitors are unconfounded by ﬁber or other com-
ponents of food and collectively represent strong evidence
supporting a possible role of low GI diets on hard end
points, i.e. CHD and T2D, even in people without diabetes
at baseline.
Questions remain as to the applicability of the GI for
general use. A key issue is what characteristics of the in-
dividual will make them more susceptible to differences in
the GI/GL of the diet. A pattern has been emerging in the
last 15 years of GI research that those with increased in-
sulin resistance, assessed as high postprandial insulin,
greater BMI, or speciﬁcally waist circumference as a
marker of central adiposity, especially in the presence of
diabetes, are likely to beneﬁt most. In particular those with
diabetes and indicators of the metabolic syndrome such as
raised systolic blood pressure [36], are most likely to have
beneﬁts from a low GI/GL diet in terms of weight reduc-
tion, diabetes control and CHD risk reduction [36e39].
Should we be designing diets for overweight people? The
Nurses’ Health Study [38] showed increased risk of CHD
with higher GL but only in those with a higher BMI. When
comparing conventional low fat diets to low GL diets those
individuals who had low insulin levels lost body weight
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lost weight on the low GL diet [37]. Many cases of cirrhosis
nowadays are a consequence of excess body weight and it
was shown that the prevalence of non-alcoholic fatty liver
was signiﬁcantly greater in people with high GI diets but
only in insulin resistant subjects [39].
Further support comes from a meta-analysis of diets for
the treatment of diabetes, where the effective diets to
reduce CHD risk in diabetes included the low GI diets [40].
Given the high prevalence of diabetes, obesity and the
metabolic syndrome worldwide, including a low GI/GL
dietary component within the context of a healthy diet
offers the prospect of reducing chronic disease and its
complications.
GI/GL/GR: methodology and issues6
GI is an index that was designed as a measure to assess the
blood glucose raising potential of the available carbohy-
drate in high carbohydrate foods, and recognizes that
equivalent amounts of carbohydrate from different foods
elicit GRs which vary over a 4e5-fold range. Due to poor
interpretation of the evidence GI has been controversial
ever since it was introduced in 1981 [15]. Recent criticisms
cast doubt upon the validity of GI, asserting that: GI does
not predict GRs, GI methodology is inaccurate and
imprecise [41e43], the calculated GI of mixed meals does
not predict their measured GI [44e46], and that many
factors inﬂuence the results. Most current criticisms are
not valid but do reﬂect a failure of knowledge translation
[47e49]. Many criticisms (eg. the GI of subjects changes
from day to day) are based on inappropriate use of the
term “GI” as if it were synonymous with “GR”. “GI” is not
“GR” and so care must be taken to use terms correctly. The
core methodology used to measure GI back in 1981 has not
changed, but a number of additional procedures and
checks have been added to improve accuracy and precision
(15). If used correctly, the GI method is precise enough to
distinguish between high-GI (GI  70, glucose scale) and
low-GI (GI  55, glucose scale) foods with 95% certainty
[49]. GI values that are not based on use of correct meth-
odology should not be termed “GI”. Alternate terms
include “GR” or “relative GR”. The calculated GI of mixed
meals is not necessarily expected to predict their GR
because the glycemic impact of a mixed meal depends not
only on its GI, but also on the amounts and types of fat,
protein and carbohydrate the diet contains. GI is a prop-
erty of high carbohydrate foods, thus it is not appropriate
to measure the GI of mixed meals. The GI of mixed meals
needs to be calculated from the GI of the carbohydrate
foods or ingredients in the meal and calculated in the same
way as we calculate the average GI of a diet. A number of
critics have raised the objection that many factors, such as
variety, processing and cooking, inﬂuence the GI of a food.
Indeed they do; but it is difﬁcult to see how this is an
argument against the use of the GI of foods; rather it is a
reason why GI is useful e how else to quantify the impact6 Author of the section: Wolever T.M.S.of variety, processing and cooking? However, that GI
values of the “same” food as given in the International GI
Tables may vary widely for some foods is a problem
because it is impossible to know the GI value of the spe-
ciﬁc food you, your client or your research subject is
actually eating. This makes clinical use of GI less accurate
than it could be, which is problematic because it may
introduce bias into study data. Further progress on GI will
be difﬁcult unless nutrition scientists and health pro-
fessionals eliminate confusing abuse of GI and agree on the
actual state of knowledge about GI. To use GI effectively,
ways to provide consumers and health professionals with
accurate and reliable information about the GI of foods
need to be developed; at the very least this will involve the
standardization and accreditation of laboratories involved
in measuring GI.
Postprandial glycemia: should we keep it low? If yes,
how?7
The epidemiological evidence suggests a direct relation-
ship between postprandial glycemia and CVD or total
mortality in people with T2DM [50,51] or without diabetes
[52,53]. Controlling postprandial glycemia results in
greater CVD beneﬁts than controlling fasting hyperglyce-
mia for the same percent reduction in HbA1c levels [54]. In
healthy people glycemia has been shown to ﬂuctuate
during the 24 h between 70 and 140 mg/dL (3.8e7.6 mmol/
L) [55]. However in the study by Ferrannini et al. [56] it is
clearly shown that already at the upper end of the normal
post-challenge blood glucose ranges (120e140 ng/mL or
6.6e7.6 mmol/L) beta-cell function drops signiﬁcantly by
60% and this seems to occur equally in lean as well as in
obese individuals. Insulin resistance and altered insulin
secretion are early signs of progressive beta cell dysfunc-
tion leading eventually to T2DM. Insulin resistance starts
with impaired secretion of ﬁrst phase insulin which is the
insulin required for controlling diet-derived blood glucose.
The consequence is postprandial hyperglycemia. We spend
most of our lives in the postprandial state since the true
fasting state occurs only in the last 2 h of a regular night
sleep [57]. Eating is followed by a surge of acetyl CoA
which combines with oxygen in the mitochondria result-
ing in the generation of ATP molecules and charged par-
ticles called free radicals. When the system is overloaded
with acetyl CoA (e.g. from over-nutrition) a larger number
of free radical products escape the mitochondria. It is
suggested that this excessive oxidative stress may be the
pathogenic mechanism underlying insulin resistance, dia-
betes and CVD [58,59]. Hyperglycemia activates many
pathways which lead to endothelial dysfunction and hence
to diabetes complications [60e62] while antioxidants such
as vitamin C and E have been shown to counterbalance the
endothelial dysfunction [62] and glutathione to normalize
blood pressure [63]. These studies support the oxidative
stress hypothesis. Managing postprandial hyperglycemia
reduced oxidative stress [64], endothelial dysfunction [65],7 Author of the section: Ceriello A.
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tein oxidation [67]. Particularly, larger blood glucose ﬂuc-
tuations have been found to induce greater oxidative stress
than constant high blood glucose levels [68]. Lower GI
foods therefore should induce smaller blood glucose ﬂuc-
tuations than higher GI foods over the day. The relation-
ship between the dietary GI and GR was examined in a
study of free-living people with T2DM and obesity using a
continuous glucose monitoring device and a simultaneous
3-day food record. The dietary GI was positively related to
blood glucose area under the curve, to mean glucose and to
the hyperglycemic ranges, while it was negatively related
to the euglycemic ranges [69]. In this study the GI resulted
as the strongest and the most consistent independent
predictor of glycemic ﬂuctuations. These data lend support
to the ecologic validity of the GI in free-living people.
Beneﬁts of low GI diets were seen also within hypocaloric
diets where the low GI component resulted in improved
endothelial function and reduced glycemic variability in
obese people without diabetes [70]. All together these
ﬁndings support the need for an optimal postprandial
blood glucose management in people with and without
diabetes. The International Diabetes Federation recognized
the relevance of prandial glucose regulation and the need
for moderating the acute surges in plasma glucose levels
following meals by making mandatory the targeting of
postprandial hyperglycemia to achieve HbA1c targets and
by developing speciﬁc guidelines on post-meal glucose
management which include the GI concept [71].
Is GI/GL of the diet important in diabetes prevention and
management?8
Traditional societies consumed largely unprocessed plant
based diets that were high in ﬁber and included whole
grains, legumes and nuts as staples. These diets were low
GI and low GL. The shift away from traditional diets to
western highly processed diets has paralleled a dramatic
rise in the prevalence of diabetes, obesity and CVD.
Epidemiological studies indicate that the consumption of
plant-based diets reduce risk of T2DM and CHD [72,73].
The “ﬁber hypothesis” suggested that this was a direct
effect of ﬁber [74]. The GI concept is an extension of the
ﬁber hypothesis suggesting that ﬁber would reduce the
rate of nutrient inﬂux from the gut [75]. It has particular
relevance to those chronic Western diseases associated
with central obesity and insulin resistance [76].
Low GI diets have been shown in clinical studies to
improve glycemic control in people with diabetes, to
improve serum lipids and other cardiovascular risk factors
and possibly to promote weight loss [4,13,77,78]. In large
epidemiological studies, consumption of low GI diets has
been associated with decreased risk of diabetes, CHD and
certain cancers [11,20,22]. Findings from recently
completed clinical trials provide further support for the
utility of the GI and GL [40,77]. In these studies, a low GI
diet signiﬁcantly improved glycemic control and decreased8 Author of the section: Kendall C.W.C.CVD risk factors in T2DM and a low GL diet was found to
improve glycemic control and blood lipids [36].
Legumes are a good source of slowly digestible carbo-
hydrate and ﬁber, making them a valuable means for
lowering the glycemic-index of the diet [77,79]. Nuts have
a healthy macronutrient proﬁle, being high in mono- and
polyunsaturated fatty acids, vegetable protein and ﬁber
and low in available carbohydrate, making them a useful
way to lower the GL of the diet. Recent ﬁndings from
clinical studies indicate that dietary approaches that
include legumes and other low GI carbohydrates, and nuts
improve glycemic control in T2DM [80]. In addition, these
dietary approaches improve cardiovascular risk factors and
markers associated with the metabolic syndrome and
contribute to CHD prevention [81,82]. These results have
been partly attributed to the slow absorption of the car-
bohydrate component of low GI foods as proved by the
acarbose pharmacological approach [31,32].
GI and GL and risk of diabetes and CVD: an epidemiologic
perspective9
The relation of GI and GL to risk of T2DM has now been
examined in many prospective studies [11,17,18,83,84].
Although positive associations have not been seen in every
study [84], dietary GI has been associated with greater risk
in the three largest studies and in a meta-analysis
combining them [85]. One of the strengths of epidemio-
logical investigations is that the variability in GI values
between different samples of the same foods is averaged
out over time in large populations. However it is still
possible to fail to detect true associations due to insufﬁ-
cient sample sizes, resulting in wide conﬁdence intervals
[86]. Strong supportive evidence for the beneﬁt of low GI
diets has been provided by the acarbose randomized trial,
in which an inhibitor of starch conversion to glucose,
which thus mimics a low GI diet, reduced the incidence of
T2DM by 36% in high risk individuals [31]. These ﬁndings
are also consistent with randomized trials among patients
with diabetes documenting physiologically signiﬁcant re-
ductions of HbA1c levels with lower GI diets [87] and with
experiments in animals in which high GI carbohydrates
showed damage to pancreatic islet cells [88]. GL has also
been directly associated with risk of T2DM, although not as
strongly as GI [85]. GL is associated with greater incidence
of CHD [6,38], although probably not among lean and
active persons with low insulin resistance, which probably
explains in part why populations in physically active
agrarian countries could, until recently, tolerate high GL
diets. In the acarbose trial described above, risk of CVD was
also reduced by 49% [32]. Overall, the dietary GI seems to
be the strongest risk factor for T2DM while GL for heart
disease. BMI, however as a surrogate for insulin resistance,
makes a substantial difference in how we respond to car-
bohydrate quality and quantity. Furthermore, there is a
third dimension to carbohydrates beyond quality and
quantity, i.e. the liquid form, which results in higher GI9 Author of the section: Willett W.C.
Table 1 Relative risk (RR) and 95% conﬁdence interval (CI) for the highest versus the lowest quantile of dietary glycemic index (GI) and glycemic
load (GL) by cancer site [23].
Cancer site GI GL
No. of studies RR (95% CI) I2 (%) No. of studies RR (95% CI) I2 (%)
Breast 19 1.05 (0.99, 1.11) 52 18 1.07 (0.98, 1.16) 68
Colon-rectum 15 1.16 (1.07, 1.25) 59 15 1.10 (0.97, 1.25) 75
Endometrium 10 1.13 (0.98, 1.32) 60 11 1.17 (1.00, 1.37) 60
Esophageal 4 1.46 (0.90, 2.38) 83 4 1.25 (0.45, 3.48) 95
Liver 4 1.11 (0.80, 1.53) 62 6 1.14 (0.78, 1.67) 70
Ovary 5 1.11 (0.85, 1.46) 74 5 1.19 (0.85, 1.68) 79
Pancreas 10 1.10 (0.99, 1.22) 0 11 1.01 (0.85, 1.19) 51
Prostate 6 1.06 (0.96, 1.18) 70 5 1.04 (0.91, 1.18) 67
Stomach 6 1.17 (0.83, 1.66) 81 6 1.10 (0.85, 1.42) 44
800 L.S.A. Augustin et al.values, reduced satiety and overconsumption, and is
associated with greater T2DM risk [89]. Given essentially
conclusive evidence that high GI/GL diets contribute to risk
of T2DM and CVD, reduction in GI and GL should be a
public health priority. One important approach would be
to replace reﬁned starches (e.g. grains and potatoes) with
whole grains, mainly intact; this also incorporates the
beneﬁts of higher amounts of ﬁber, minerals and vitamins.
The concept of GI is valuable in understanding the effects
of diet on risk of chronic disease. Whether this should be
explicitly part of widespread dietary advice and included
in food labeling is less clear. Although we should avoid
overly focusing on a single attribute of any food, some
information on carbohydrate quality is essential for the
public to make optimal dietary choices.GI/GL and risk of major cancers: what can we conclude
based on epidemiological evidence?10
Dietary carbohydrates increase blood glucose and insulin
concentrations at different rates and levels depending on
their GI [15]. A direct association has long been found
between diabetes and cancer [90] and hyperinsulinemia/
hyperglycemia may be a contributing factor in this rela-
tionship [91,92], while some anti-hyperglycemic medica-
tions (i.e. metformin) seem to beneﬁcially alter it [93].
Insulin acts as a growth factor increasing the bioactivity of
the cancer-promoting insulin-like growth factor-1 (IGF-1)
which has proliferatory, angiogenic, anti-apoptotic and
estrogen-stimulating properties [94,95]. It has been pro-
posed that low GI foods by virtue of their lower glucose
rises and overall insulin economy may beneﬁcially inﬂu-
ence cancer risk compared to high GI foods [96]. System-
atic reviews and meta-analyses indicate that the dietary GI
is moderately and directly associated with breast and
colorectal cancer risk with pooled relative risk (RR) of
1.1e1.2 for the highest versus the lowest GI level, and less
consistent associations were found with endometrial
cancer [11,21,97].
We have therefore updated a previous meta-analysis
[97] to January 2015 with available data on GI and GL and
all cancer sites, in both cohort and caseecontrol studies,10 Authors of the section: La Vecchia C. and Augustin L.S.using random effects models [23]. The pooled RRs were
above unity for all cancer sites. The RR for the highest
versus the lowest GI and GL quantiles were respectively:
1.16 (signiﬁcant) and 1.10 for colorectal, 1.05 and 1.07 for
breast, 1.13 and 1.17 for endometrial cancer, 1.06 and 1.04
for prostate cancer (see Table 1 for all results). There was
signiﬁcant heterogeneity among studies which was not
explained by publication bias.
If real, such associations would be explained by the
higher impact of high GI/GL foods on glycemia, insuline-
mia and insulin-like growth factors which may promote
tumor growth [98]. These associations would be of rele-
vance on a prevention and public health level, considering
the high incidence of several of these neoplasms. There are
however uncertainties in interpreting these results,
considering the moderate associations, the heterogeneity
across studies and study design (cohort versus case-
econtrol) and possible inadequate allowance for con-
founding or interactions with other aspects of diet and
carbohydrate composition, including body weight and
metabolic syndrome. Moreover, in general, interpretation
of any RR from observational studies (cohort and case-
econtrol) of the order of 1.1e1.2 requires due caution.Dietary carbohydrates and metabolic outcomes:
assessing the totality, consistency and quality of
epidemiologic observations and clinical interventions11
Nutrition is a complex issue with many factors and vari-
ables exerting an inﬂuence on metabolic health and inci-
dence of disease. Regardless of whether studies are
interventional or observational, heterogeneities abound in
nutritional studies of health outcomes. These heteroge-
neities are measured with standard meta-analytical
methods. The simplest of meta-analyses assume that all
studies in the meta-analysis share one true effect size
(ﬁxed effects), but this rarely occurs. Two approaches that
assess determinants of heterogeneity are subgroup anal-
ysis and meta-regression. The former is useful to distin-
guish between inﬂuential factors (e.g. men versus women)
whereas the latter is better for continuous variables (e.g.
age, BMI, severity of disease). Care should be taken when11 Authors of the section: Livesey G. and Liu S.
12 Author of the section: Sievenpiper J.L.
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eeresponse or severity of a metabolic perturbation, which
is not uncommon, because can be misleading about the
position on the continuum that any effect is evident.
Furthermore, factoring sexes as subgroups may be difﬁcult
or suboptimal when many studies are of mixed gender and
of varying proportion of each sex. However, sex proportion
is a variable that is assessable in meta-regression. Meta-
regression also has potential for the building of models to
explain how key variables relate to one another. Recent
use of meta-analytical methods has been illuminating in
understanding the role of GI/GL/GR in the development
and management of key metabolic diseases, especially
when the number of original studies is large enough to
provide sufﬁcient statistical power. We discuss herein
some examples concerning T2DM and CHD. A compre-
hensive systematic meta-regression analysis of published
prospective cohort studies of the T2DM-GL risk relation
has explained 97% of heterogeneity among studies [19,99].
Women [19] and men [99] each have a signiﬁcantly higher
risk of T2DM when consuming diets of high GL across a
wide range of GL values above 95 g GL/2000 kcal diet, with
women at higher risk than men. The ﬁndings are sufﬁcient
to realize that in the lower reaches of GL this risk can be
reduced by choosing lower GI foods. For the higher reaches
of GL, as attained across populations worldwide, aiming
for a target of 100 g GL/2000 kcal would need also a
reduction in the amount of carbohydrate in the diet, which
is an energy source that appears to elevate the risk less
than does GL [100]. Together with gender, other explana-
tions of heterogeneity found were ethnicity (European-
Americans versus all other ethnicities combined), the
number and validity of the dietary instrument used to
assess the amount of carbohydrate eaten, length of follow-
up, and type of T2DM assessments. The validity of the
dietary assessment approach has demonstrated a marked
underestimation of the role of GI/GL/GR in relation to risk
of T2DM in many studies.
Turning to meta-regression of controlled intervention
trials (mostly randomized controlled trials), lower GL diets
achieved by reducing GI have reduced (improved) both
fasting blood glucose and glycated proteins in patients with
T2DM [12]. These effects are additional to improvements
obtainedbyglucosecontrollingdrugs.Heterogeneity in these
studies was explained by the severity with which blood
glucose control was impaired, and by differences for inci-
dental amounts of dietary ﬁber ingested between the treat-
ment and control arms within studies. These beneﬁts, of
lower GL and higher ﬁber intake, and of lower GI and higher
ﬁber intake were additive. This ﬁnd is consistent with the
original similarﬁnds for incident T2DM inprospective cohort
studies for both men [17] and women [18]. Together these
meta-regression analyses show risk reduction among pop-
ulationsof bothhealthy persons andpatients diagnosedwith
T2DM, with sources of heterogeneity mostly explained. An
additional, central plank for diabetes prevention and man-
agement is body weight control management [101,102].
Meanwhile early meta-regression analyses have indicated
body weight reduction can occur with GL reductionprogressively given time and sufﬁciently large GL reduction
[12,103], determinants of heterogeneity that are not best
assessed by subgroup analysis. CHD is prevalent among
populations and especially T2DM patients. To date meta-
analyses indicate, as for T2DM, a stronger beneﬁcial rela-
tion between CHD and lower GI/GL/GR in non-diabetic
women more than in men among prospective cohort
studies [6,20,104]. Reasons for difference between men and
women in respect of both incident T2DM and incident CHD
remain to be elucidated. When undertaking original epide-
miological studies and subsequentmeta-analyses,much due
attentionstill needs tobegivento theuseandreportingof the
adequacy of dietary instruments used to assess food intakes
[11,19,105]. Outside the context of instrument validation,
whether men are less accurate thanwomenwhen reporting
food they eat is unclear. If it is true that the assessment is less
accurate for men, then it would result in underestimation of
the risk among men and might be responsible for gender
difference in the effects of GI/GL/GR on T2DM and CHD.
Foods low in GI/GL/GR need to be eaten in the context
of a healthy diet. In this context there is little need to be
concerned about the fructose content of compliant diets.
However, it cannot be assumed that current food-based
healthy eating advice will improve or optimize the GI/GL/
GR of foods eaten both because these values are very
heterogenous among food groups advised and because
current compositional advice emphasizes the quantity,
rather than the quality of carbohydrates. Indeed, it is
possible to select a vast number of high GI foods and still
be compliant with advice; this evenwhen the advice arises
from national authorities or from hitherto lifestyle inter-
vention studies of T2DM. Therefore, there is a need to
reconsider or revise current dietary recommendations
with an emphasis on GI/GL/GR.
Fructose the low-GI sugar: is there cause for concern?12
There was initially an interest in fructose as an alternative
sweetener in people with diabetes owing to its low-GI [15].
Othermolecularmechanismswere subsequently described,
whereby low-doses of fructose were shown to improve the
metabolic handling of glucose through the induction of
glucokinase resulting in increases in glycogen synthesis and
decreased hepatic glucose output [106e108]. Translation of
these ﬁndings in the acute clinical setting has shown that
small so called ‘catalytic’ fructose doses (10 g/meal) can
reduce the postprandial GRs to high-glycemic index meals
from 15 to 30% [109e111]. The interest in fructose, however,
has recently focused on its harm. Over the past decade,
fructose has become a focus of intense concern regarding its
role in the epidemics of obesity, diabetes, and their car-
diometabolic complications. There have been dozens of
editorials, commentaries, and letters in the scientiﬁc liter-
ature and numerous pieces in the lay media calling for ef-
forts to restrict its intake. Ecological observations which
have linked increasing fructose intake with increasing
obesity and diabetes rates along with animal models and
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exposure far beyond actual population levels of intake have
driven this debate [112e116]. To address theuncertainties in
extrapolating from these data and to support international
diabetes and heart association guidelines, a series of sys-
tematic reviews and meta-analyses of the highest level of
evidence from prospective cohort studies (clinicaltrials.gov
identiﬁer, NCT01608620) and controlled feeding trials
(Clinicaltrials.gov identiﬁer, NCT01363791) [117] has been
undertaken. Although large prospective cohorts studies
have shown signiﬁcant positive associations with incident
obesity, diabetes, gout, CHD, and stroke when comparing
the highest with the lowest levels of intake of sugar-
sweetened beverages, these associations do not hold true
atmoderate levels of intake orwhenmodeling total fructose
(with the exception of gout) [118]. Similarly, the evidence
from controlled feeding trials shows that there is a reason-
able body of consistent evidence from controlled feeding
trials that fructose in isocaloric exchange forother sources of
carbohydrate at low-to-moderate doses near the average
U.S. intake of fructose (w10% total energy) [119] does not
have adverse effects [79,120e125]. There may even be
beneﬁts for bloodpressure [122] andglycemic control [121],
especially at low doses (‘catalytic’ doses,10 g/meal) which
are equivalent to levels obtainable from fruit [126]. There is,
however, an emerging body of consistent evidence that
fructose providing excess energy (þ18e97% excess energy)
at extreme doses (>100-g/day) well above the 95th-
percentile for U.S. intake (7) may promote weight gain,
dyslipidemia, raised uric acid levels, and non-alcoholic fatty
liver disease (NAFLD), effects which may be more attribut-
able to excess energy than fructose [120,123e125,127].
Taken together, higher level evidence in humans does not
support the view that fructose is harmful at typical intakes.
Lowdoses of fructose (10 g/meal) at levels obtainable from
fruit may even have advantages for glycemic control and
blood pressure and be a useful way for lowering the glyce-
mic index of some foods. The shorter duration, poor quality
and unexplained inter-study heterogeneity among the
available trials indicate the need for larger, longer-term
feeding trials to guide our understanding of the effect of
fructoseoncardiometabolic risk. There is also aneed for true
ad libitum trials to assess whether fructose when freely
replaced with other sources of energy likely to replace it in
the diet leads to differences in energy intake, weight gain,
and downstream cardiometabolic risk.
Effects of GI/GL on satiety and body weight13
Should future nutritional recommendations for the general
population take into account the notion of GI? This ques-
tion is all the more legitimate as the glycemic response to
foods seems to be a factor that affects satiety and could
therefore affect food intake. Consumption of low GL foods
is expected to result in a reduced postprandial rise of in-
sulin [75], thus altering availability of metabolic fuels after
a meal [3,76,128]. After a high GI/high GL meal, blood13 Author of the section: Rizkalla S.W.glucose and insulin levels initially rise much higher than
after a low GI/low GL meal, leading therefore to stimula-
tion of cellular nutrient uptake, inhibition of hepatic
glucose production, and suppression of lipolysis. Subse-
quent declines in blood glucose concentration induced by
the relative hyperinsulinemia of a high GI diet have been
proposed to induce excessive hunger and overeating. High
GI diets have therefore been hypothesized to promote
excessive weight gain. Several studies in adults
[76,128,129], in children and in adolescents reported
decreased hunger, increased satiety, and decreased
voluntary food intake in response to low GI/low GL meals
in acute conditions. Ludwig et al. [128] reported higher
ratings of hunger and greater energy intake after a high GI
meal in a randomized crossover study comparing high GI
to low GI meals in 12 adolescent boys. Ball et al. [129]
reported a 48-min prolongation of satiety after a low GI
versus a high GI supplement in a similar crossover study of
16 adolescents, but found no differences in hunger ratings
or changes in actual energy intake. Such crossover meal
studies have the advantages of a within-subjects design
that controls for many extraneous factors that may
complicate human studies. Short-term treatment studies
have described beneﬁcial effects of low GI or GL diets on
body weight and composition. Slabber et al. [130] reported
greater weight loss after 3 months among obese women
who were counseled to eat low GI foods compared with
those who did not receive this advice. Bouche et al. [131]
found that fat mass decreased more in overweight men
after 5 weeks on a low GI compared with a high GI diet. In
overweight subjects with increased insulin secretion, 18
months of a low GI diet also increased weight loss [37]. A
modest increase in protein content together with a low GI-
hypocaloric diet for 4 weeks, decreased adipocyte size, a
phenotype of adiposity, and tended to decrease body
weight and fat mass [133]. A signiﬁcant weight loss was
achieved after 12 weeks on such a diet [134]. Additionally,
“DIOGenes” (diet, obesity and genes) randomized clinical
trial from eight European countries [78], a diet moderately
high in protein and low GI prevented weight regain and
reduced body fat mass following a weight loss program.
The low GI was an independent contributor. Long term
dietary weight loss programs using low GI diets succeeded
to induce a decrease in fat mass albeit not always in body
weight. However, a low GI diet may decrease body weight
in some special cases, in gestational women and in sub-
jects with higher postprandial insulin secretion. Impor-
tantly, the demonstration of the efﬁcacy of a low GI diet
combined with high protein to prevent weight regain over
the long term could have major public health signiﬁcance.
GI and GL during childhood and adolescence and its
relevance for metabolic outcomes14
Evidence from cohort studies in children and adolescents
regarding the role of a lower dietary GI/GL in the pre-
vention of overweight is presently inconclusive. In14 Author of the section: Buyken A.E.
15 Author of the section: Brand-Miller J.C.
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the DONALD Study, a lack of association was observed both
between dietary GI/GL and BMI/body fat and between
changes in dietary GI/GL and changes in BMI/body fat
during three time windows (childhood, adolescence, from
puberty to adulthood, nZ 215e380) [136e138]. Similarly,
changes in GI or GL during a 2-year follow-up were not
associated with changes in adiposity measures in a group
of 85 overweight US American adolescents of Latin-
American origin [139]. Conversely, among 279 Australian
adolescent girls an increase in dietary GL during the 5-year
follow-up was related to concurrent increases in BMI and
waist circumference [140]. With respect to the role of low
GI/GL diets in the treatment of obesity, initial evidence
from a small pilot [141] and a retrospective study [132]
suggested a superiority of low GL diets for weight loss in
obese children and adolescents. However, this was not
conﬁrmed by recent intervention studies (duration 3e24
months) performed on larger pediatric samples
[135,142,143]. Nonetheless, in the DiOGenes study the
combination of GI and protein intake was related to a
decrease in overweight or obesity rates among children on
a diet higher in protein and lower in GI [135]. Thus, data
available to date does not support a strong role of GI or GL
in the prevention or treatment of childhood obesity, yet
the relevance of a lower dietary GI in combination with
higher protein content should be further elucidated in
observational and intervention studies.
Evidence on the relevance of GI/GL for risk markers of
T2DM and CVD in children and adolescents is still
emerging. Smaller intervention studies suggest some
beneﬁts of low GI/GL diets speciﬁcally for insulin resis-
tance [141,144,145]. However, in a recent 2-year interven-
tion on 113 obese Hispanic children the examined diets did
not differ in their effect on changes in insulin resistance or
markers of the metabolic syndrome [142]. Similarly, in a
sub-sample of 253 children and adolescents participating
in the DiOGenes study, dietary GI did not affect cardio-
vascular risk markers [146]. Conversely, prospective cohort
studies suggest long-term adverse health consequences of
a habitually higher GI or GL during adolescence. In an
Australian adolescent cohort, increases in dietary GI and
GL between age 12 and 17 years were related to substantial
concurrent increases in systolic blood pressure among 278
girls [147]. In a sample of 226 healthy German adolescents,
a habitually higher dietary GI during puberty was the only
feature of carbohydrate nutrition that was consistently
related to higher insulin resistance and higher markers of
hepatic steatosis in younger adulthood [148]. In addition,
in the same cohort higher intakes of carbohydrate from
high GI sources during puberty were prospectively asso-
ciated with higher adult levels of IL-6 [149].
Consideration of the GI in the diet of children and ado-
lescents is of long-term relevance, since nutritional behav-
iors are shaped during childhood and adolescence. Of note,
analysis of dietary GI in a representative sample of Austra-
lian children and adolescents revealed that a preferred se-
lection of carbohydrates from low GI sources may indeed
confer beneﬁts for overall nutrient adequacy [150]. Bycontrast, adherence to the current recommendations to
increase whole grain consumption and/or reduce intake of
sugary foods cannot be expected to translate into a lower
dietary GI/GL. Associations of dietary GI to dietary ﬁber are
neither strong nor uniform across pediatric populations
[151,152]. In the DONALD cohort, 76% of the whole grains
consumed by healthy adolescents came from sourceswith a
higher dietary GI (GI 55) [149], which reﬂects the fact that
many whole grain products have a relatively high GI [16].
Also, contrary to the popular belief a higher dietary sugar
intake is not related to a higher dietary GI [153], because all
common sugars, except glucose, are of moderate (sucrose)
or low GI (fructose and lactose) [16]. Since dietary GI is not
closely related to dietary ﬁber or dietary sugar intake it
needs to be addressed as a separate entity in nutritional
recommendations given to children and adolescents. Ef-
forts to reduce the dietary GI and GL in children and ado-
lescents should best be targeted to energy-dense starchy
food, since these make a considerable contribution to total
dietary GL in children and adolescents [151,152].
GI/GL/GR: are all methods of reducing postprandial
glycemic responses equally beneﬁcial?15
There are multiple dietary strategies that reduce post-
prandial glycemia, including 1) reducing the carbohydrate
intake as a percentage of energy, 2) increasing the intake
of nutrients that slow gastric emptying (e.g. fat, protein,
viscous ﬁber and acidity), 3) incorporating nutrients that
increase insulin secretion (e.g. protein, speciﬁc amino
acids and fat), 4) reducing the GI of the main carbohydrate
foods (by reducing starch gelatinization, increasing viscous
ﬁber or fructose content) or 5) using pre-loads (e.g. small
amount of alcohol, fructose or protein), or a combination
of these approaches. Not all of these approaches are
associated with beneﬁcial effects. Indeed, striving for the
lowest level of postprandial glycemia possible may not be
desirable.
In practice, energy-standardized GL is a good predictor
of the level of postprandial glycemia associated with a
particular food or diet [154]. In cohort studies, GL, but not
carbohydrate content, has been frequently linked to
reduced risk of T2DM [19] and CVD [11]. In randomized
controlled trials, diets with a reduced GL, including higher
protein/moderate carbohydrate diets [78], Mediterranean
diets [155] and low GI diets [134], have been linked to
improved weight control and risk factors for T2DM and
CVD. Very low carbohydrate-high protein diets also have
beneﬁcial effects on weight control and some cardiovas-
cular risk factors (not LDL-cholesterol) in the short term,
but are associated with increased mortality in long term
cohort studies [156]. In practice such diets include large
amounts of animal protein and/or red meat, both of which
have been linked to increased risk of T2DM [100].
Hence, at the present time, aiming for a moderate
reduction in postprandial glycemia using low GI,
Mediterranean-style and higher protein-moderate
804 L.S.A. Augustin et al.carbohydrate diets is safe and helpful. Some whole grains
or minimally processed grain foods (e.g. steel-cut oats,
quinoa or pumpernickel bread) as well as viscous ﬁbers
(psyllium, beta-glucans, and PGX) also reduce post-
prandial glycemia, but the majority of whole grain foods
do not. The lowest level of postprandial glycemia is ach-
ieved using very low carbohydrate-high protein diets, but
these cannot be recommended for long term use.
GI as affected by the presence of proteins/amino acids16
Recent research has highlighted the importance of dietary
protein in satiety and weight maintenance. Thus, a diet
characterized by a slightly lower GI and a moderately
higher protein content was more efﬁcient in counteracting
weight gain after a period of energy restriction and weight
loss [78]. Also, high protein diets consumed ad lib
improved metabolic risk markers in children of over-
weight parents [146]. However, the current knowledge
regarding the metabolic impact of the type of protein is
scarce. Of interest in this respect are reports indicating that
dairy proteins, by virtue of increasing satiety and pro-
moting skeletal muscle growth, have advantageous effect
on metabolic health [157]. In particular, whey protein ap-
pears to induce beneﬁts on risk factors associated with the
metabolic syndrome [158]. Consistent with a protective
role of dairy proteins, an increase in dairy intake signiﬁ-
cantly attenuated markers of oxidative and inﬂammatory
stress in subjects with the metabolic syndrome [159]. It
cannot be excluded that other milk components beyond
protein may play a role e.g. vitamin D and calcium. How-
ever, a possible explanation for the improved metabolic
variables could be the capacity of certain proteins to lower
the postprandial glycemic responses.
The presence of certain proteins, and/or amino acids
(AA) reduce postprandial glycemia to glucose, or com-
posite meals in healthy subjects. When comparing lactose
equivalent amounts of meals containing different proteins,
whey in particular was found to stimulate insulin response
and reduce postprandial glycemia [160]. Whey ingestion
promoted higher levels of the AA’s lysine, threonine,
valine, iso-leucine and leucine, and the effects of whey on
glycemia and insulinaemia following a carbohydrate
challenge could essentially be mimicked by oral ingestion
of a protein equivalent mixture of these ﬁve AA’s provided
in a ratio as appeared in postprandial blood following
ingestion of whey protein [161]. Similar effects of whey
protein on glycemia and insulinemia to an oral glucose
challenge in healthy subjects has been reported also by
others, and appeared to be unaffected by the fasting
insulinemic state [162]. A doseeresponse relationship was
established, such that each gram of added whey protein
decreased blood glucose incremental area under curve
(0e120 min) by 3.8 mmol min/L [163]. Also certain plant
proteins e.g. soy, may reduce glycemia to a carbohydrate
challenge in healthy subjects. Whey proteins favorably
affect acute glycemia of composite meals also in people16 Author of the section: Björck I.with T2DM [165], and longer term dietary supplementa-
tion with essential AA’s improved markers of metabolic
control in diabetes. Consequently, in poorly controlled
T2DM oral supplementation with essential AA’s, improved
a measure of insulin resistance (HOMA IR) and decreased
HbA1c compared with placebo [166]. Recent studies
further indicate that timing of protein ingestion may be of
importance. A “pre-meal” load of whey protein supple-
mented with leucine, iso-leucine, valine, threonine and
lysine, stimulated an early GLP-1 response and reduced
blood glucose after a composite carbohydrate rich meal in
healthy subjects in the absence of differences in post-
prandial peak insulin or overall incremental insulin re-
sponses compared with the same meal ingested with
water [164]. Whey intake with the meal or as a “pre-meal”
load prior to a composite meal, signiﬁcantly reduced gly-
cemic response in people with T2DM compared with a
reference meal without whey [167]. The pre-meal load in
particular induced higher GLP-1 responses in the post-
prandial period compared with the reference meal, indi-
cating an incretin effect also in people with diabetes.
Suggested mechanisms for beneﬁts on acute glycemia
following co-ingestion of carbohydrates with proteins and/
or amino acids may include insulinogenic effects of certain
AA and/or stimulation of incretins [160], reduced gastric
emptying rate [167], decreased hepatic insulin extraction,
increased C-peptide clearance [162] or improved insulin
sensitivity [168].
It is concluded, that in addition to the GI characteristics
of carbohydrates in foods/meals, the glucose regulatory
properties of co-ingested proteins may also inﬂuence
postprandial glycemia. The potential of low GI/high pro-
tein diets should be further evaluated in relation to weight
regulation, glycemic regulation and risk factors for the
metabolic syndrome, with attention paid to the quality of
different food proteins. Also, different food proteins and/or
AA-mixtures may be exploited to lower postprandial gly-
cemia in healthy subjects and in T2DM.
Mediterranean diet, GL and diabetes: evidence from EPIC-
Greece17
An EPIC-wide study, based on 24-h recalls, indicated that
population groups from Mediterranean regions, the diet
of whom tends to conform more closely to the traditional
Mediterranean diet, tend to also be of lower GL, although
the pattern was not without exceptions. Moreover, in a
study based on food frequency questionnaires adminis-
tered to more than 20,000 participants in the Greek EPIC
cohort, the association between conformity to the Medi-
terranean diet and GL, although positive, was rather
weak, so that the GL of diets with high conformity to the
Mediterranean diet was 27% higher in comparison to
diets with low conformity to the Mediterranean diet
[169]. This indicates that it is quite feasible to envisage
dietary patterns compatible with the traditional Medi-
terranean diet and yet be characterized by low GL.17 Author of the section: Trichopoulou A.
Table 2 Glycemic index (GI) in European dietary reference values
(DRVs).
EU country DRV on GI
France The 2004 document from the French Agency ANSES
concluded that the level of evidence is insufﬁcient
to provide indications on GI based on health
beneﬁts for the general population and prohibited
the use of GI labeling or any derived measures
[173].
Germany The recently issued German Nutrition Society DRV
document reports that: “to date there is only possible
evidence regarding a risk-increasing effect of high
Glycaemic Index on some nutrition-related diseases.
Therefore, no recommendations are made in that
respect” [174].
Nordic
Countries
Nordic Nutrition Recommendations 2012 conclude
that “There is not enough evidence that choosing foods
with low Glycaemic Index will decrease the risk of
chronic diseases in the population overall. However,
there is suggestive evidence that ranking food based
on their Glycaemic Index might be of use for
overweight and obese individuals” [175].
Italy The recently issued DRVs from the Italian Society of
Human Nutrition, included under “Suggested
Dietary Targets” generic qualitative indications on
preference for low-Glycemic Index foods when
intakes of carbohydrates approach the upper limit
of intake, i.e. 60% energy. They also speciﬁed the
need of preferentially selecting low GI foods
provided the GI was not reduced by adding fructose
and/or fat [176].
UK The Scientiﬁc Advisory Committee on Nutrition
(SACN) has recently attempted a comprehensive
opinion on carbohydrate and health. The document,
a compromise between DRVs and Food-Based
dietary Guidelines for the UK population, was
published for public consultation at the end of June
2014 [177]. The Committee concludes that “it is not
possible to assign cause-effect relationships for
outcomes based on variation in diet Glycaemic Index
Scientiﬁc consensus on glycemic index and load 805Indeed, the contribution of olive oil to the energy intake
in the Greek traditional Mediterranean diet (around 20%)
allows the identiﬁcation of a relevant dietary pattern. We
have therefore evaluated the association of high confor-
mity to the Mediterranean diet/low GL dietary pattern
with certain chronic diseases, e.g. T2DM. The results
showed that a high adherence to the Mediterranean diet
was inversely associated with T2DM risk (OR Z 0.88, CI:
0.77e0.99, p trendZ 0.021) while combining it with low
GL the association became stronger (OR Z 0.82, CI:
0.71e0.95). These results suggest that a low GL combined
with a traditional Mediterranean diet conveys 18% pro-
tection against the occurrence of T2DM [169] suggesting
that even within an overall healthy diet there may be
beneﬁts of lowering the dietary GL.
An update on the health claims in Europe and some
considerations about reducing GI/GL in the context of
European diets18
Postprandial glycemia can inﬂuence a number of physio-
logical responses linked to long-term health maintenance
and/or disease risk, and has been advocated as a useful
parameter describing the quality of dietary carbohydrates.
In Europe, the European Food Safety Authority (EFSA) is
the independent body acting as the scientiﬁc support to
risk managers of the EU government and member states.
An intense activity has been performed in the last few
years by the EFSA Dietetic products, Nutrition and Al-
lergies (NDA) panel for the authorization of health claims
made on foods. According to the NDA panel, the criteria
that should be taken into consideration to demonstrate a
health effect of foods or food ingredients are rather
straightforward: the indicated effect must be a beneﬁcial
physiological effect; the active ingredient to which the
effect is related should be clearly identiﬁed and charac-
terized; if this is the case, the effect of displacing un-
healthy components must be assessed; the amount of the
ingredient required to elicit the claimed effect must be
compatible with a balanced diet and, ﬁnally, there must be
sufﬁcient scientiﬁc evidence to support it. A speciﬁc
guidance was issued by EFSA in 2012 about the re-
quirements for health claims related to blood glucose
concentrations [170]. Regarding the ﬁrst criterion, reduc-
tion of post-prandial glycemic response (PGR) was
considered a beneﬁcial physiological effect, provided in-
sulin is not disproportionally increased. A number of well
characterized food ingredients including sugar replacers,
resistant starch and some ﬁbers, have been authorized to
bear the PGR reduction claim (for reference, please consult
the EU register of authorized health claims http://ec.
europa.eu/nuhclaims/).
Among available carbohydrates, fructose has gained
positive opinion, as EFSA found it effective in reducing PGR
when replacing at least 30% of sucrose and/or glucose (i.e.
a comparative claim) [171]. On the contrary, no claims
were allowed for 14 other carbohydrate foods which were18 Author of the section: Brighenti F.related to their GI or GR. The general impression is that the
GI methodology was not considered by the competent
authorities solid enough to represent a benchmark for
food characterization. A likely next step from the food
industry may be to use the PGR of carbohydrate foods
comparatively to equi-carbohydrate amounts of glucose, as
already accepted for fructose. This however may increase
confusion among consumers since without a standard
comparator no properranking of the foods is possible.
Indeed, the importance of considering food classiﬁcation
based on GI/GL in food selection is little if none endorsed
by the bodies issuing dietary recommendations in the
European Union and the member countries.
In 2010 EFSA issued the European Dietary Reference
Values (DRV) document for carbohydrate [172]. The panel
found the evidence for GI and GL inconclusive, and
therefore made no speciﬁc recommendations. Other Eu-
ropean countries have taken the GI into consideration
when preparing national DRV documents with contrasting
results (Table 2) [173,174].or Load, as higher or lower GI and GL diets differ in
many ways other than just the carbohydrate fraction”.
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consideration must be achieved before dismissing the
contribution of low GII foods to a healthy diet. First of all
we should acknowledge that a growing proportion of the
European population, though apparently healthy, presents
conditions that may signiﬁcantly affect glucose meta-
bolism, such as aging, sedentary lifestyle and overweight
and thus could especially beneﬁt from a reduction of
postprandial glucose response. Although EFSA requires the
target population to be “healthy”, given the high preva-
lence of metabolic conditions it is indeed advisable to test
GI/GL in studies which do not exclude these high risk in-
dividuals. Moreover, we must recognize that differences
among diets consumed in different European countries
exist and are quite large. This heterogeneity might very
well represent a beneﬁt in nutrition research since it may
help to clarify the role of GI on health. Indeed, there are
large regional differences in the proportion of energy
derived from carbohydrates [178] and in the characteris-
tics of the carbohydrate foods. Therefore there may be a
need to have country-speciﬁc GI databases which would
help assess with more precision both GI exposures and
disease risk. It is plausible that the determinants of the
dietary GI and GL between populations may differ and
that speciﬁc country-based GI databases might help to
evaluate with more precision the exposure and hence
disease risk [179].
Finally, we should not forget that in Europe, as well as
in other continents, dietary habits are constantly evolving
in the light of rapidly changing factors such as demog-
raphy, commodity supply, product innovation, regulations,
consumers’ beliefs and the overall economy of the
different countries. Traditional ways to identify dietary
patterns, such as country-speciﬁc diets, might also evolve
according to such factors. Therefore, additional efforts are
required in order to properly update the information on
European diets, interpreting existing data and designing
future studies to assess the relationships between diet and
health and their determinants.
GI claims on foods: the Australian experience19
Rates of overweight/obesity, T2DM and their sequelae are
increasing around the globe in both developed and
developing nations [180]. Healthy low GI foods and drinks
can be incorporated into prevention and/or management
plans for many of these conditions, helping to reduce the
global disease burden [11,78,181,182]. Availability of
healthy low GI foods and drinks for purchase is often cited
as a barrier to recommending the use of the GI [183]. Even
when they are available, easy identiﬁcation of healthy low
GI choices amongst the many thousands of food choices
available within an average supermarket is another po-
tential barrier. Few nations regulate the use of GI claims on
food and drink labels [184]. However, most food pur-
chasing decisions are made at the point of sale [185], so
having the GI on labels may help people make healthier19 Author of the section: Barclay A.W.food choices, helping them prevent/manage weight, dia-
betes, CVD and certain cancers [11,78,181,182].
As well as including nutrition information like GI values
in Nutrition Facts/Nutrition Information Panels, there is
growing interest globally in the development of front-of-
pack labeling schemes to assist consumers with healthy
food purchasing decisions [186].
The GI Symbol is a front-of-pack labeling scheme that
also includes the requirement to include a GI value in the
Nutrition Facts/Nutrition Information Panel. It was regis-
tered as a Certiﬁcation Trademark (CTM) in AustraliaeNew
Zealand, North America, the EU, and Asian nations be-
tween 2002 and 2015. In order to utilize the CTM (GI
Symbol), foods must be low GI according to ISO
26642:2010 [187] and also meet stringent nutrient criteria
for energy (kJ or kcal), carbohydrate, saturated fat, sodium,
and in certain foods ﬁber and calcium [188]. Nutrient
criteria are in line with international dietary guidelines
[189].
The GI Symbol was launched in Australia in 2002 [190].
Market research was conducted in Australia by Newspoll
prior to the launch [191], and then annually until 2007,
and then again in 2012 [192]. Survey participants were
490e1502 main grocery buyers representative of the
Australian adult (aged 18þ years) population and living in
the 5 mainland capital cities (Adelaide, Brisbane, Mel-
bourne, Perth and Sydney) of Australia.
In 2002, 5 foods carried the GI Symbol and this increased
to over 150 foods by 2013 [190]. In 2002, 28% of respondents
(nZ490)were aware of theGI [190]. This increased to 86%of
respondents (nZ 458) by 2005, and has remained approx-
imately the same from that point in time onwards [191].
Awareness of the GI Symbol was 2% at baseline [190], and
increased to 37% by 2012 (nZ 1502) [191]. Most (94%) con-
sumers who were aware of the GI looked for the GI Symbol
when shopping [191]. The majority (80%) believe that the GI
Symbol indicates that foods that carry it are “healthy,
wholesome and a good choice”, “scientiﬁcally tested” and
“provide sustained energy/glucose release” [191].
In conclusion, the GI Symbol program is a simple front-
of-pack labeling tool that helps people to identify healthy
low GI foods when shopping. Awareness of both the GI and
the GI Symbol increased rapidly upon introduction of the
tool into the Australian food environment. It is envisaged
that a similar uptake will be achievable in other nations
when the GI Symbol Program is progressively rolled out.
Do low GI/GL diets improve traditional and novel
cardiovascular risk factors including chronic
inﬂammation?20
In many epidemiological studies low GI/GL diets have been
found to be associated with a lower risk of cardiovascular
events. This association could be mediated by a favorable
impact of this type of diet on cardiovascular risk factors. As
a matter of fact, this hypothesis is plausible since obser-
vational studies have consistently shown that in people20 Author of the section: Riccardi G.
Scientiﬁc consensus on glycemic index and load 807having a habitual diet with a lower GI/GL, most cardio-
vascular risk factors are reduced; this holds true also after
taking into account the overall composition of the diet
[193].
In order to validate this association, intervention trials
are needed. The majority of these studies are focused on
blood glucose and plasma lipids. In general they are
concordant in showing a beneﬁcial effect of low GI/GL
diets on plasma glucose values (particularly during the
post-prandial period) and on plasma (LDL) cholesterol
levels; this applies both to people with diabetes and
without [24,194,195]. The favorable impact on plasma total
and LDL cholesterol seems to be much more relevant when
the low GI/GL diet is also ﬁber rich [196]. As for other lipid
classes, the studies indicate that lowering the GL but not
the GI of the habitual diet is able to reduce plasma tri-
glyceride levels and to increase plasma concentrations of
HDL [24,197]. In this respect, it may be relevant to consider
that a favorable impact of a low GI/GL diet on plasma tri-
glycerides may be attenuated if this diet includes a high
proportion of low GI foods and beverages rich in sucrose/
fructose, since it has been reported that a high fructose or
sucrose intake predisposes to triglyceride elevations and to
HDL decrease [198]. In addition, the impact of different
foods on plasma insulin levels could also modulate their
effects on plasma triglycerides and on HDL, especially in
obese individuals, and this could also explain some in-
consistencies of the relationship between dietary GI/GL
and plasma lipid levels [199]. It has been suggested that
race/ethnicity and body mass index may have an effect on
these associations, however, this needs to be conﬁrmed in
larger studies. Also markers of subclinical inﬂammation (c-
reactive protein, CRP) are consistently reduced by a low GI
diet; data on the effects of low GL are, instead, less
concordant [29]. However, so far this aspect has only been
evaluated in a small number of studies. Among other
features of the metabolic syndrome, there is no effect of
GI/GL on blood pressure in healthy subjects although
Acarbose as a pharmacological model of low GI, reduces
incidence of hypertension in individuals with impaired
glucose tolerance [32], while there is a modest but
reproducible inﬂuence on body weight; the data on insulin
sensitivity are few and not always concordant but, overall,
they indicate a beneﬁcial effect [200].
A new area of interest for intervention studies on GI/GL
diets is the evaluation of post-prandial lipemia; there are
many epidemiological and pathophysiological studies
indicating that elevations of plasma triglyceride levels
(and excessive increases of triglyceride rich lipoproteins)
after a meal are associated with an increased predisposi-
tion to atherosclerosis. The impact of low GI/GL diets on
post-prandial metabolism is the background evidence of
many intervention trials aiming at evaluating the inﬂuence
of diet on metabolic abnormalities in the post-prandial
period. They have clearly shown that in patients with
diabetes a low GL diet improves the overall metabolic
response in the postprandial period by reducing: plasma
glucose levels, plasma insulin values, glycemic variability,
hypoglycemic events and plasma concentrations oftriglyceride-rich lipoproteins; further studies are needed
in non-diabetic people [195,196,201].
Conclusions
The scientiﬁc summit on the health effect of carbohydrate
quality reached a consensus on all the points summarized
in Table 3. The panel recognized postprandial glycemia as a
relevant factor in overall health and considers dietary ap-
proaches that slow carbohydrate absorption to be useful
tools in lowering the risk of major chronic diseases and
related risk factors. One of these tools is represented by the
low GI aspect of carbohydrate foods and the panel recog-
nized that the GI methodology is reproducible and valid to
express the glycemic response of foods in a standardized
fashion (Table 3). The panel found strong evidence from
clinical trials that low GI diets moderately improved gly-
cemic control in type 1 and 2 diabetes, with evidence for
beneﬁts in blood lipids and inﬂammatory markers in
people with and without diabetes (Tables 3 and 4). The
panel recognized a strong association between lower di-
etary GI/GL in reducing the risk of developing T2DM in
men and women and CHD risk mainly in women (Tables 3
and 4). These health advantages may be of greater rele-
vance in individuals who are sedentary, overweight and in
those with the insulin resistance condition (Tables 3 and
4). Despite the lack of clinical trials investigating the role
of low GI in reducing the risk of developing T2DM and
heart disease, the experience with alpha-glucosidase in-
hibitors, which convert meals into low GI meals, suggests a
potential role of low GI in disease risk reduction end points
(Table 4). The evidence was found to be moderate to weak
for a possible protective role of low GI/GL diets in cancer
risk (Table 4) and in metabolic outcomes in childhood and
adolescence although some beneﬁts may be seen in in-
dividuals with insulin resistance. However, low GI diets
may have health advantages in youth since they related to
overall improvements in nutrient proﬁles. The panel
recognized a probable role of low GI and GL diets in body
weight management. In adults, low GI diets tended to have
a greater impact on reducing body fat mass than body
weight while weight loss was mainly observed in over-
weight people with high insulin levels. However, after
weight loss, the combination of low GI and higher protein
may prevent weight regain. Despite the indication of the
effect of low GI and GL foods in reducing postprandial
glucose response which is considered a beneﬁcial physio-
logical effect by EFSA, very little consensus was found
within the European DRV documents for the use of low GI.
Only Scandinavian countries and Italy suggested the use of
low GI diets but in selected groups, i.e. in overweight and
obese people and in those whose dietary carbohydrate
intakes reach 60% of total calories, with a warning
regarding foods where low GI is a consequence of high
levels of fructose or fats. However the concern that the low
GI sugar fructose may adversely affect metabolic makers
when in substitution for equivalent amounts of other
sources of carbohydrate likely to replace it (mainly reﬁned
starch, glucose, or sucrose) was not supported by the
Table 3 Consensus: scientiﬁc statements [1e14] and future rec-
ommendations [15e20].
1. Carbohydrates present in different foods have distinct
physiological effects, including effects on postprandial gly-
cemia, also known as the glycemic response (GR), with
different implications for health.
2. Reducing postprandial glycemia is recognized as a beneﬁcial
physiological effect [52,53,202,203].
3. Ways to reduce postprandial glycemia include slowing
carbohydrate absorption by consuming low glycemic index
(GI) and low glycemic load (GL) foods to reduce the dietary
GI and GL [15,18].
4. The GI methodology is a sufﬁciently valid and reproduc-
ible method for differentiating foods based on their GR
[49,204].
5. The GI quantiﬁes speciﬁc physiological properties of
carbohydrate-containing foods as inﬂuenced by the food
matrix. These characteristics extend beyond the chemical
composition of the foods and include delaying gastric
emptying and reducing the rate of digestion and small
intestinal absorption.
6. When considering the macronutrient composition, the GL/
1000 kJ (the product of GI and available carbohydrate con-
tent) is the single best predictor of the GR of foods [154].
7. There is convincing evidence from meta-analyses of
controlled dietary trials that diets low in GI improve
glycemic control in people with type 2 and type 1 diabetes
[12,13,77,87,194].
8. There is convincing evidence from meta-analyses of
prospective cohort studies that low GI/GL diets reduce the
risk of type 2 diabetes [11,19].
9. There is convincing evidence from a large body of pro-
spective cohort studies that low GI/GL diets reduce the risk
of coronary heart disease [6,38,205].
10. The proof of principle for the concept of slowing carbohy-
drate absorption is the use of alpha-glucosidase inhibitors
(acarbose etc.) to reduce progression to type 2 diabetes and
coronary heart disease [31,32].
11. The quality of carbohydrate rich foods as deﬁned by GI/GL is
particularly important for individuals who are sedentary,
overweight and at increased risk of type 2 diabetes [3,18].
12. Potential mechanisms for reduction of type 2 dia-
betes include evidence that low GI/GL diets improve
insulin sensitivity and beta-cell function in people with
type 2 diabetes and those at risk for type 2 diabetes
[206,207].
13. Potential mechanisms for reduction of coronary heart
disease include evidence that low GI/GL diets improve blood
lipids and inﬂammatory markers including C-reactive
protein [24,27e29,193,208,209].
14. Probable evidence exists for low GI/GL diets in reducing
total body fat mass and in weight management
[37,78,131,134,210].
15. The GI complements other ways of characterizing
carbohydrate-foods, such as ﬁber and whole grain content
[201,211].
16. Low GI and low GL should be considered in the context of a
healthy diet.
17. Given the rapid rise in diabetes and obesity there is a need
to communicate information on GI/GL to the general public
and health professionals.
18. This should be supported by inclusion of GI/GL in dietary
guidelines and in food composition tables.
19. In addition package labels and low GI/GL symbols on
healthy foods should be considered.
20. More comprehensive high-quality food composition tables
need to be developed for GI/GL at the national level.
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moderate. The panel supports the use of the dietary GI and
GL labeling in the context of a healthy diet complementing
other healthy dietary attributes (e.g. high ﬁber) as with the
Australian GI Symbol. A front-of-pack label could be used
that also requires foods to meet healthy nutrient criteria in
line with international dietary guidelines. In light of the
epidemic of conditions affecting glucose metabolism, the
panel strongly believes that the dietary GI and GL should be
communicated to the general public and health pro-
fessionals through dietary guidelines, country-speciﬁc GI
databases, food composition tables and food labels (Table 3).
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